Dermata Therapeutics, Inc.
corporate_fare Company Profile
Dermata Therapeutics, Inc. (NASDAQ:DRMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for DRMA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for DRMA spans 10-Q, 8-K, SCHEDULE 13D, 424B3.
Recent high-impact activity:
- Dermata Q3: First Tome Revenue of $74K, $4.8M Cash, Going Concern Reaffirmed
- Dermata Posts First $74K in Product Sales, But Cash Runs Dry by Q1 2027
- Dermata Secures $3.4M Private Placement with Insider Backing
- Dermata Q2 Cash Drops to $4.4M, Runway Only Into Q4; Going Concern Warning Reiterated
- Dermata Posts Q2 Loss, Targets August 25 Debut for First Skincare Line
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 84,233 shares in DRMA as of the October 30, 2026 settlement, a 9.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 45.8% of DRMA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for DRMA, detected from its recent SEC filings · based on capital-structure filings through 2026-05-29.
Universal Shelf Offering Finalized · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →